Catalyst Pharmaceutical (CPRX) closed the last trading session at $24.96, gaining 0.5% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. The mean price target of $34 indicates a 36.2% upside potential.The average comprises eight short-term price targets ranging from a low of $31 to a high of $40, with a standard deviation of $2.98. While the lowest estimate indicates an increase of 24.2% from the current pri ...

Core Viewpoint - The article emphasizes the importance of confirming the sustainability of a trend in short-term investing, highlighting that successful entry timing is crucial for capitalizing on price movements [1][2]. Group 1: Trend Analysis - The trend can reverse before exiting a trade, potentially leading to short-term capital losses for investors [2]. - A stock's recent price strength is a key indicator of its potential to maintain upward momentum, with a focus on stocks trading in the upper portion of their 52-week high-low range [3][5]. Group 2: Company Spotlight - Catalyst Pharmaceutical (CPRX) - Catalyst Pharmaceutical (CPRX) has shown a solid price increase of 13.7% over the past 12 weeks, indicating investor confidence in its potential upside [4]. - CPRX has maintained a price increase of 0.5% over the past four weeks, suggesting that the upward trend is still intact [5]. - The stock is currently trading at 89.5% of its 52-week high-low range, indicating a potential breakout [5]. Group 3: Fundamental Strength - CPRX holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate revisions and EPS surprises [6]. - The Zacks Rank system has a strong historical performance, with Zacks Rank 1 stocks averaging an annual return of +25% since 1988 [7]. - The Average Broker Recommendation for CPRX is 1 (Strong Buy), reflecting high optimism from the brokerage community regarding its near-term price performance [7]. Group 4: Investment Strategy - The article suggests that CPRX may continue its price trend without reversal in the near future, and encourages exploring other stocks that meet similar criteria [8]. - Investors are advised to utilize various Zacks Premium Screens to identify potential winning stock picks based on their investment style [8].

Gary Ingenito, MD, PhD is retiring from Catalyst after a successful careerCORAL GABLES, Fla., June 02, 2025 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX) today announced the appointment of William (Will) T. Andrews, MD, FACP as Chief Medical Officer. Dr. Andrews will report directly to the Company’s President and Chief Executive Officer, Richard J. Daly, and will serve as a member of the Company’s executive leadership team. He succeeds Dr. Gary Ingenito, who is ...

Group 1 - The article emphasizes that investing is a learning process, where failures serve as tuition and successes contribute to lessons learned [1] - The author has approximately five years of focused research on various stocks, with a primary emphasis on healthcare stocks in recent years [1] Group 2 - There is no current stock, option, or similar derivative position in any of the companies mentioned, but there may be plans to initiate a beneficial long position within the next 72 hours [2] - The article expresses the author's own opinions and is not influenced by any business relationships with the companies mentioned [2]

Catalyst Pharmaceuticals (CPRX) 2025 Conference May 14, 2025 11:00 AM ET Speaker0 Here with our next company presenter at the BofA Annual Healthcare Conference. I'm pleased to be introducing our next company presenter Catalyst Pharmaceuticals and Richard Ailey, President and Chief Executive Officer and Steve Miller, COO and CSO. My name is Jason Gerberry. I cover SpitCat Biotech and Specialty Pharma at BofA. And so Catalyst, a commercial stage rare orphan focused company in growth mode and has a sort of a l ...

Catalyst Pharmaceuticals (CPRX) reported adjusted earnings of 68 cents per share for the first quarter of 2025, beating the Zacks Consensus Estimate of 53 cents. The company had recorded adjusted earnings of 38 cents in the year-ago quarter.Total revenues, the majority of which comprised product revenues, amounted to $141.4 million in the reported quarter, representing growth of 44% year over year. The recorded figure also surpassed the Zacks Consensus Estimate of $130 million.Catalyst Pharmaceuticals’ top ...

Catalyst Pharmaceuticals (CPRX) Q1 2025 Earnings Call May 08, 2025 08:30 AM ET Company Participants Michael Kalb - Executive VP & CFORichard Daly - President & CEOJeff Del Carmen - Executive Vice President, Chief Commercial OfficerBenjamin Paluch - Equity Research Senior Associate - BiotechCharles Duncan - Managing DirectorRohan Mathur - Biopharma Equity Research AssociateGary Ingenito - Chief Medical & Regulatory OfficerFelix Ampomah - Senior Associate Conference Call Participants Asim Rana - Equity Analys ...

Financial Data and Key Metrics Changes - Total net revenues increased by 43.6% year over year to $141,400,000, with significant contributions from all products [4][26] - Net income before income taxes for Q1 2025 was $71,300,000, a 145% increase year over year [28] - GAAP net income for Q1 2025 was $56,700,000, or $0.47 per basic share, reflecting a 144% increase year over year [28] - Non-GAAP net income for Q1 2025 was $86,600,000, or $0.71 per basic share, compared to $46,800,000 in Q1 2024 [28][29] Business Line Data and Key Metrics Changes - Firdapse generated revenue of $83,700,000, a 25.3% increase year over year [6][27] - Agamry's net product revenues totaled $22,000,000, compared to $1,200,000 in Q1 2024, marking its first full year of commercial availability [9][27] - Fycompa's net product revenue was $35,600,000, representing a year-over-year growth of 17.1% [11][28] Market Data and Key Metrics Changes - Approximately 20% to 25% of current Firdapse patients are cancer-associated LEMS patients, with expectations to increase this percentage through screening initiatives [49][90] - The market for LEMS is estimated at $1,200,000,000, with the company currently holding about 25% market penetration [94] Company Strategy and Development Direction - The company aims to expand its market leadership for Firdapse and Agamry while managing the transition of Fycompa post-patent expiry [12][15] - Strategic initiatives include enhancing patient access and focusing on business development opportunities that align with the company's goals [15][75] - The company is committed to advancing health equity by expanding access to therapies for underserved populations [14] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in sustaining growth momentum and achieving full-year revenue guidance of $545,000,000 to $565,000,000 [16][26] - The company is focused on executing strategic priorities and maintaining operational excellence [15][36] Other Important Information - The company ended Q1 2025 with cash and cash equivalents of $580,700,000, an increase from $517,600,000 at the end of 2024 [34] - Research and development expenses for Q1 2025 were $3,900,000, up from $2,600,000 in Q1 2024, reflecting ongoing investments in clinical studies [33] Q&A Session Summary Question: What contributed to Firdapse's growth this quarter? - Management indicated that approximately 15% to 20% growth is typical, and the strong performance in Q1 was partly due to recovery from the Change Healthcare incident [39][41] Question: What is the proportion of Fycompa patients on tablet versus oral suspension? - Approximately 85% of Fycompa patients are on the tablet formulation [44][62] Question: How is the uptake of Firdapse among small cell lung cancer patients? - Currently, 20% to 25% of LEMS patients on Firdapse are cancer-associated, with plans to increase this through screening efforts [49][90] Question: What are the company's current thoughts on business development? - The company remains focused on identifying immediately accretive opportunities and sees the current market dynamics as beneficial for its strategy [54][56] Question: How does the company plan to minimize brand erosion for Fycompa post-exclusivity? - Management noted that there is a tendency for anti-seizure medications to retain patients, which may help minimize brand erosion [70][72] Question: What is the company's market penetration for Firdapse? - The company estimates a market penetration of about 25% for Firdapse, with significant growth potential remaining [94][96]

Catalyst Pharmaceutical (CPRX) reported $141.42 million in revenue for the quarter ended March 2025, representing a year-over-year increase of 43.6%. EPS of $0.68 for the same period compares to $0.38 a year ago.The reported revenue represents a surprise of +8.92% over the Zacks Consensus Estimate of $129.84 million. With the consensus EPS estimate being $0.53, the EPS surprise was +28.30%.While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectatio ...

Catalyst Pharmaceutical (CPRX) came out with quarterly earnings of $0.68 per share, beating the Zacks Consensus Estimate of $0.53 per share. This compares to earnings of $0.38 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 28.30%. A quarter ago, it was expected that this specialty drug company would post earnings of $0.52 per share when it actually produced earnings of $0.70, delivering a surprise of 34.62%.Over the last four ...